- Home
- NEWT vs CRVS Comparison
NEWT vs CRVS Comparison
Compare NEWT & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEWT
- CRVS
- Stock Information
- Founded
- NEWT 1998
- CRVS 2014
- Country
- NEWT United States
- CRVS United States
- Employees
- NEWT N/A
- CRVS N/A
- Industry
- NEWT Major Banks
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- NEWT Finance
- CRVS Health Care
- Exchange
- NEWT Nasdaq
- CRVS Nasdaq
- Market Cap
- NEWT 294.8M
- CRVS 305.4M
- IPO Year
- NEWT N/A
- CRVS 2016
- Fundamental
- Price
- NEWT $12.37
- CRVS $5.75
- Analyst Decision
- NEWT Hold
- CRVS Strong Buy
- Analyst Count
- NEWT 4
- CRVS 4
- Target Price
- NEWT $13.00
- CRVS $15.00
- AVG Volume (30 Days)
- NEWT 188.9K
- CRVS 518.7K
- Earning Date
- NEWT 07-28-2025
- CRVS 08-07-2025
- Dividend Yield
- NEWT 6.14%
- CRVS N/A
- EPS Growth
- NEWT 21.23
- CRVS N/A
- EPS
- NEWT 2.01
- CRVS N/A
- Revenue
- NEWT $364,004,000.00
- CRVS N/A
- Revenue This Year
- NEWT N/A
- CRVS N/A
- Revenue Next Year
- NEWT $12.73
- CRVS N/A
- P/E Ratio
- NEWT $6.15
- CRVS N/A
- Revenue Growth
- NEWT 20.91
- CRVS N/A
- 52 Week Low
- NEWT $9.12
- CRVS $2.54
- 52 Week High
- NEWT $15.49
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- NEWT 61.20
- CRVS 65.10
- Support Level
- NEWT $12.16
- CRVS $5.28
- Resistance Level
- NEWT $12.48
- CRVS $5.64
- Average True Range (ATR)
- NEWT 0.27
- CRVS 0.30
- MACD
- NEWT 0.02
- CRVS 0.03
- Stochastic Oscillator
- NEWT 73.00
- CRVS 77.70
About NEWT NewtekOne Inc.
NewtekOne Inc is a financial holding company engaged in providing financial solutions to its Client Base. It is an internally managed non-diversified closed-end management investment company. It has four reportable segments Banking, Alternative Lending, Technology, NSBF, and Payments.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).